摘要

Authors' objectives: This health technology assessment evaluates the effectiveness, safety, and cost-effectiveness of gene expression profiling (GEP) tests for people with early-stage invasive breast cancer. It also evaluates the budget impact of publicly funding GEP tests and the experiences, preferences, and values of people with early-stage invasive breast cancer.